This information is designed to provide healthcare workers in Queensland with an understanding of thrombosis with thrombocytopenia syndrome (TTS) also known as vaccine induced prothrombotic immune thrombocytopenia (VIPIT). It is intended as a guide only and does not replace sound clinical judgement.

As our accepted understanding of this syndrome is rapidly evolving, do not print this factsheet. Please refer to our vaccine page or Frontline Advice emails for the latest advice.

Key messages

- A very small proportion of patients globally have developed thrombocytopenic thrombotic syndrome following vaccination with COVID-19 Vaccine AstraZeneca.
- No specific risk factors have been identified and causality has not yet been proven.
- Prevalence is very rare (4-6 per million).
- The benefits of COVID-19 vaccines outweigh the risk of TTS/VIPIT for most people, especially in a high-risk COVID environment.
- People who have had the first dose of COVID-19 Vaccine AstraZeneca without any serious adverse effects can be given the second dose, including adults under 50 years of age.
- Vaccination against COVID-19 should continue, with the Pfizer COVID-19 vaccine the preferred option in those under 50 years of age.

What is the issue?

In late March 2021, potential safety concerns involving cases of thrombosis (blood clots) and thrombocytopenia (low blood platelet count) occurring after vaccination with COVID-19 Vaccine AstraZeneca were under investigation. On 2 April 2021 the Australian Technical Advisory Group on Immunisation (ATAGI) reported that a probable case had been reported in an Australian vaccine recipient, and issued updated advice for healthcare providers.

Since this time, it has emerged that a very small proportion of patients have developed thrombocytopenic thrombotic syndrome following a COVID-19 vaccination (the European Medicines Agency reports 169 cases of CVST, 53 cases of SVT, with 18 deaths). Thrombosis with thrombocytopenia syndrome (TTS) is a rare and new syndrome. The condition involves blood clots (occurring in body sites like the brain or abdomen) together with low platelet levels. The syndrome has some similarity to heparin induced thrombocytopenia (HIT) and has also been termed “vaccine induced prothrombotic immune thrombocytopenia” or VIPIT.

Investigators in Europe have reported the detection of antibodies against platelet antigens PF4 as part of the immune stimulation post vaccination.

While data from around the world is incomplete, incidence is considered to be extremely rare (4-6 per million). Cases have been described in the UK, Germany, France, and Scandinavia but further scientific work is still pending.

A causal link with the AstraZeneca vaccine is not proven but is possible. Further investigation is underway.
When should I suspect TTS/VIPIT?

The Thrombosis and Haemostasis society of Australia and New Zealand (THANZ) has released an initial statement which will be updated as more evidence becomes available. THANZ summarises the features of TTS/VIPIT cases (as of 31 March 2021) as:

- Onset 4-20 days after vaccination
- Thrombosis: predominance of cerebral venous sinus but splanchnic and other VTE also reported
- Thrombocytopenia (severity and trajectory of thrombocytopenia unclear)
- High D-Dimer (typically very high)
- Some patients are refractory to standard anticoagulation
- Some reports of response to Intravenous immunoglobulin (IVIG)

While the European Medicines Agency (EMA) has not identified any specific risk factors, such as age, gender or a previous medical history of clotting disorders for these very rare events, most cases of TTS/VIPIT described to date have been female and under 60 years of age. Males have also been affected, and it is believed the sex-adjusted rates are similar. Some cases report progression of thrombosis whilst on therapeutic heparin anticoagulation.

Patients presenting with organ specific symptoms of thrombosis (such as severe headaches unresponsive to simple analgesia, abdominal pain or respiratory symptoms) 4-20 days after vaccination should be reviewed carefully for signs of thrombosis or bleeding. Other neurological symptoms of cerebral vein thrombosis can include those of raised intracranial pressure such as visual changes, severe headache, seizures, focal neurological deficits, and general symptoms of encephalopathy including confusion.

As multiple sites have been involved (cerebral venous sinus, splanchnic, pulmonary embolism), any patients presenting with symptoms of thrombosis shortly after vaccination should be considered carefully for TTS/VIPIT. As a precaution, patients with this suspected condition should NOT receive any heparin or platelet transfusions. These treatments may potentially worsen the clinical course.

How do I investigate for TTS/VIPIT?

THANZ advises that appropriate investigations should always be initiated based on the patient context. Do not delay the commencement of life-saving management while awaiting investigations. However, while suspicion of TTS/VIPIT is explored:

- Do not administer platelet transfusions.
- Do not begin heparin-based anticoagulation (IV unfractionated heparin infusions, LMWH).

The following screening is advised:

- A full blood count and blood film (platelet count <100x10^9/L).
- Coagulation screen including fibrinogen (level may be low) and D-dimer level (level will be over 2x upper limit of normal).
- Appropriate targeted imaging.

If TTS/VIPIT is suspected:

- Further serum and plasma samples must be taken (at least 4 x blue top citrate tubes and 2 serum clot tubes) for additional confirmation tests (available at all larger Pathology Queensland laboratories).
- If there is clinical suspicion and other criteria met, consult your local haematologist regarding further testing, ensuring they are aware of the clinical suspicion of TTS/VIPIT.
• Complete an Adverse Event Following Immunisation (AEFI) form.

Most cases of suspected TTS/VIPIT will require the commencement of management without the opportunity to assess for PF4 or PF4/polyanion antibodies. Specialist consultation with haematology will be required.

THANZ advises if there are no contraindications, treating all thrombotic events for patients who have recently received COVID vaccination (within the last 28 days), with a non-heparin anticoagulant (e.g. fondaparinux or DOAC - apixaban or rivaroxaban), even if VIPIT testing is negative. Consultation with a sub-specialist thrombosis haematologist is recommended.

What does this mean for the rollout of the AstraZeneca vaccine?

The risk-versus-benefit assessment for the use of AstraZeneca COVID-19 vaccine will be different for Australia compared to other countries, such as those with widespread transmission and very serious outbreaks.

The risk of serious disease and death in Australia remains, even as borders controls and other measures continue. The AstraZeneca vaccine is highly effective at reducing the risk of death or severe disease from COVID-19 across all adult age groups, and at the present time, is the only vaccine option for reducing this risk for many Australians, since the global availability of alternative vaccines is highly constrained.

Following consultation between the Australian Health Protection Principal Committee (AHPPC), the ATAGI and the Therapeutic Goods Administration (TGA), on 8 April 2021 the Australian Government announced four changes to the COVID-19 vaccine rollout that come into effect immediately:

1. At the current time, use of Pfizer COVID-19 vaccine is preferred over COVID-19 Vaccine AstraZeneca in adults under 50 years of age who have not already received a first dose of AstraZeneca vaccine. This is based on the increased risk of complications from COVID-19 with increasing age (and thus increased benefit of vaccination), and the potentially lower, but not zero, risk of thrombosis with thrombocytopenia syndrome with increasing age.
2. Immunisation providers should only give a first dose of COVID-19 Vaccine AstraZeneca to adults under 50 years of age where the benefit clearly outweighs the risk for that individual’s circumstances.
3. People who have had their first dose of COVID-19 Vaccine AstraZeneca without any serious adverse effects can be given their second dose. This includes adults under 50 years of age. People who have had blood clots associated with low platelet levels after their first dose of COVID-19 Vaccine AstraZeneca should not be given their second dose.
4. The Australian Department of Health will further develop and refine resources for informed consent that clearly convey the benefits and risks of the AstraZeneca COVID-19 vaccine for both immunisation providers and consumers of all ages.

Risk benefit discussion

If Pfizer is contraindicated or not available, discuss risks and benefits for the individual as per below and in addition to the above. If a consumer wishes to proceed, then proceed with informed consent.

• If an individual cannot access Pfizer vaccine for any reason, do they have risk factors which might increase their exposure to COVID-19 in the workplace, their environment or at home? What is their risk of severe disease? They may also have individual reasons for not wishing to access the AstraZeneca vaccine and self-perceived risk which should be explored and discussed.

• As one example, healthcare workers aged under 50 working in a COVID-19 ward with COVID-19 positive patients may benefit from vaccination to reduce their risk of severe disease should they contract COVID-19 in the course of their work.
• Any person aged under 50 years wishing to receive the AstraZeneca vaccine should be fully informed about thrombosis in combination with thrombocytopenia as a rare but serious side effect before vaccination.
• The UK’s Winton Centre for Risk and Evidence Communication Analysis is useful to describe different exposure risks for age groups.
• The aim of the current vaccination program is primarily around preventing severe disease for individuals who contract COVID-19.
• We respect a person’s choice to make an informed decision on whether to accept the risk of COVID-19 vaccination with the AstraZeneca vaccine.

Reporting a TSS/VIPIT AEFI

An Adverse Event Following Immunisation (AEFI) is a serious, uncommon or unexpected event following immunisation. Under the Public Health Act 2005 and the Covid-19 Vaccination Code, Covid-19 vaccine service providers are required to report any adverse events following immunisation directly to Queensland Health. Common side effects such as headache and fatigue are to be expected and do not need to be reported.

A patient is only considered to have thrombosis with thrombocytopenia syndrome if they have blood clotting AND a low platelet count, occurring between 4-20 days after a COVID-19 vaccination.

Click here to complete an Adverse Event Following Immunisation (AEFI) form.

Recommended reading

• GTH statement on vaccination with the AstraZeneca COVID-19 vaccine as of March 22, 2021
• Science Table (Canada)
• Australian Technical Advisory Group on Immunisation (ATAGI) statement 8 April 2021